Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 20/20 | 0.67 |
| ▸ | PPARA | Q07869 | 12/20 | 0.67 |
| ▸ | PPARG | P37231 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812103 | 0.92 | PPARD (0.56) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL4808548 | 0.92 | PPARD (0.55) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL4809692 | 0.90 | PPARD (0.54) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL4807884 | 0.88 | PPARD (0.47) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL4811835 | 0.86 | PPARD (0.52) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL4809514 | 0.83 | PPARD (0.69) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL4807344 | 0.83 | PPARD (0.42) | PPARDPPARAPPARGMEN1MAPT | |
| SCHEMBL5517495 | 0.83 | PPARD (0.82) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL4801459 | 0.83 | PPARD (0.82) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL5526136 | 0.83 | PPARD (0.76) | PPARDPPARAPPARGMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449468-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-09-27 | — | — | US | disclosed |
| US-7229998-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-03-29 | — | — | US | disclosed |
| EP-1349843-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1368011-A1 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1349843-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002067912-A2 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES OR CONDITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002059098-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | PPARD, PPARG, PPARA | PPARD 1/4885PPARA 3/4885PPARG 2/4885 |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885PPARG 3/4885 |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885PPARG 1/4885 |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.